» Articles » PMID: 10996789

Genetic Suppression of Phenotypes Arising from Mutations in Dystrophin-related Genes in Caenorhabditis Elegans

Overview
Journal Curr Biol
Publisher Cell Press
Specialty Biology
Date 2000 Sep 21
PMID 10996789
Citations 44
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Dystrophin is the product of the gene that is mutated in Duchenne muscular dystrophy (DMD), a progressive neuromuscular disease for which no treatment is available. Mice carrying a mutation in the gene for dystrophin (mdx mice) display only a mild phenotype, but it is aggravated when combined with a mutation in the MyoD gene. The nematode worm Caenorhabditis elegans has a dystrophin homologue (dys-1), but null mutations in dys-1 do not result in muscle degeneration.

Results: We generated worms carrying both the dys-1 null mutation cx18, and a weak mutation, cc561ts, of the C. elegans MyoD homologue hlh-1. The double mutants displayed a time-dependent impairment of locomotion and egg laying, a phenotype not seen in the single mutants, and extensive muscle degeneration. This result allowed us to look for genes that, when misexpressed, could suppress the dys-1; hlh-1 phenotype. When overexpressed, the dyc-1 gene - whose loss-of-function phenotype resembles that of dys-1 - partially suppressed the dys-1; hlh-1 phenotype. The dyc-1 gene encodes a novel protein sharing similarities with the mammalian neural nitric oxide synthase (nNOS)-binding protein CAPON, and is expressed in the muscles of the worm.

Conclusions: As a C. elegans model for dystrophin-dependent myopathy, the dys-1; hlh-1 worms should permit the identification of genes, and ultimately drugs, that would reverse the muscle degeneration in this model.

Citing Articles

Aligning with the 3Rs: alternative models for research into muscle development and inherited myopathies.

Mehmood H, Kasher P, Barrett-Jolley R, Walmsley G BMC Vet Res. 2024; 20(1):477.

PMID: 39425123 PMC: 11488271. DOI: 10.1186/s12917-024-04309-z.


Cardiomyopathy in Duchenne Muscular Dystrophy and the Potential for Mitochondrial Therapeutics to Improve Treatment Response.

Gandhi S, Sweeney H, Hart C, Han R, Perry C Cells. 2024; 13(14.

PMID: 39056750 PMC: 11274633. DOI: 10.3390/cells13141168.


Cross-species modeling of muscular dystrophy in Caenorhabditis elegans using patient-derived extracellular vesicles.

Shalash R, Levi-Ferber M, Cohen C, Dori A, Brodie C, Henis-Korenblit S Dis Model Mech. 2024; 17(3).

PMID: 38501170 PMC: 11007864. DOI: 10.1242/dmm.050412.


HLH-1 Modulates Muscle Proteostasis During Larval Development.

Nisaa K, Ben-Zvi A Front Cell Dev Biol. 2022; 10:920569.

PMID: 35733850 PMC: 9207508. DOI: 10.3389/fcell.2022.920569.


Animal models for researching approaches to therapy of Duchenne muscular dystrophy.

Zaynitdinova M, Lavrov A, Smirnikhina S Transgenic Res. 2021; 30(6):709-725.

PMID: 34409525 DOI: 10.1007/s11248-021-00278-3.